Validant, a transatlantic quality, compliance and regulatory consulting group, acquired DataRevive, a regulatory strategy and consultancy firm that focuses on supporting pharma and biotech to navigate the regulatory approval pathway for global clients in the US market.
The amount of the deal was not disclosed.
The acquisition of DataRevive is part of Validant’s international growth strategy through both organic expansion and selective acquisitions and follows its partnership with GHO Capital, a specialist healthcare investment adviser based in London, in December 2018.
The combination of the two companies will strengthen and expand the combined group’s service offering across regulatory driven life science consulting and allow both businesses to serve their clients across the development lifecycle.
The acquisition adds a new location in Washington D.C. to complement Validant’s existing presence in San Francisco, the Research Triangle Park in North Carolina and Cork, Ireland. With many international clients, DataRevive also broadens the group’s exposure to and expertise in significant new growth markets.
Established in 2016 by Audrey Jia, CEO, DataRevive is a Regulatory Affairs consulting firm, providing high quality advice and expertise from the perspective of industry and regulators to support customers from across pharma and biotech as they seek to navigate the regulatory approval process.
Led by Brian Burns, CEO, Validant is an international Quality, Compliance, and Regulatory consulting firm, combining industry expertise with innovation to create custom solutions for companies on the frontier of health. Validant has deep experience working within and alongside the FDA, health authority, and other regulatory agencies.